Atherothrombotic disease is now the leading cause of mortality in the world and there are only a few methods available to estimate risk of vascular disease. Vascular disease risk assessment methods have been developed from a variety of population based studies and the most frequently used approaches include algorithms developed by Framingham (USA), Munster (Germany), and SCORE (Europe). The field of risk estimation is dynamic and inclusion of newer factors and populations is under active consideration and methods such as discrimination and calibration are now available to evaluate the use of risk assessment tools across different world regions.
DrouetL. Atherothrombosis as a systemic disease. Cerebrovasc Dis2002; 13 (Suppl 1):1–6.
2.
World Health Organization. The World Health Report 2002: Reducing risks, promoting healthy life. Geneva: World Health Organization.
3.
LichtmanJHKrumholzHMWangYRadfordMJBrassLM. Risk and predictors of stroke after myocardial infarction among the elderly: results from the Cooperative Cardiovascular Project. Circulation2002; 105:1082–1087.
4.
GrundySMPasternakRGreenlandPSmithSFusterV. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation1999; 100: 1481–1492.
5.
Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA Project) www.ktl.fi/monica. Last accessed 2 November 2004.
6.
ParkYWZhuSPalaniappanLHeshkaSCarnethonMRHeymsfieldSB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Int Med2003; 163:427–436.
7.
JonssonSHedbladBEngstromGNilssonPBerglundGJanzonI. Influence of obesity on cardiovascular risk. Twenty-three-year follow-up of 22 025 men from an urban Swedish population. Int J Obes2002; 26:1046–1053.
8.
LakkaHMLaaksonenDELakkaTANiskanenLKKumpusaloETuomilehtoJSalonenJT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA2002; 288:2709–2716.
9.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomized placebo-controlled trial. Lancet2002; 360:7–22.
10.
FoxKAA. An introduction to the Global Registry of Acute Coronary Events. Eur Heart J2000; 21 (Suppl F):F21–24.
11.
The GRACE investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J2001; 141: 190–199.
12.
StegPGGoldbergRJGoreJMFoxKAEagleKAFlatherMD, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol2002; 90: 358–363.
13.
FoxKAGoodmanSGKleinWBriegerDStegPGDabbousOAvezumA. Management of acute coronary syndromes. Variations in practice and. outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J2002; 23:1177–1189.
14.
FoxKAACokkinosDVDeckersJ. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J2000; 21:1440–1449.
15.
RoeMTOhmanEMPollackCVPetersenEDBrindisRGHarringtonRA, et al. Changing the model of care for patients with acute coronary syndromes. Am Heart J2003; 146:605–612.
16.
YusufSFlatherMPogueJHuntDVarigosJPiegasL, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet1998; 352:507–514.
17.
MaynardCWeaverWDLambrewCBowlbyLJRogersWJRubisonMR. Factors influencing the time to administration of thrombolytic therapy with recombinant tissue plasminogen activator (data from the National Registry of Myocardial Infarction). Participants in the National Registry of Myocardial Infarction. Am J Cardiol1995; 76:548–552.
18.
BarronHVBowlbyLJBreenTRogersWJCantoJGZhangY, et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation1998; 97:1150–1156.
19.
KullerLHVelentgasPBarzilayJBeauchampNJO'LearyDHSavagePJ. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol2000; 20:823–829.
20.
LenfantCChobanianAVJonesDWRoccellaEJ. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension2003; 41:1178–1179.
21.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA2001; 285:2486–2497.
22.
D'AgostinoRBGrundySSullivanLMWilsonP. Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation. JAMA2001; 286:180–187.
23.
LiuJHongYD'AgostinoRBJr.WuZWangWSunJ, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA2004; 291:2591–2599.
24.
WilsonPWF. Framingham and European risk algorithms: implications for African Americans. Rev Cardiovasc Med2004; 5:S34–41.
25.
ConroyRAPyoralaAPFitzgeraldAPSansSMenottiADe BackerG, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J2003; 24:987–1003.
26.
Bastuji-GarinSDeverlyAMoyseDCastaigneAManciaGde LeeuwPW, et al. Intervention as a goal in Hypertension Treatment Study Group. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens2002; 20:1973–1980.
27.
BrownMJPalmerCRCastaigneAde LeeuwPWManciaGRosenthalT, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000; 356:366–672.
28.
KurthTGazianoJMBergerKKaseCSRexrodeKMCookNR, et al. Body mass index and the risk of stroke in men. Arch Intern Med2002; 162:2557–2562.
29.
ZhangXFAttiaJD'EsteCYuXH. Prevalence and magnitude of classical risk factors for stroke in a cohort of 5092 Chinese steelworkers over 13.5 years of follow-up. Stroke2004; 35:1052–1056.
30.
UeshimaHLimuraOLidaMOkayamaASawaiKMinowaMYanagawaH. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese—Nippon data 80. J Hum Hypertens2003; 17:851–857.
31.
KuboMKiyoharaYKatoITanizakiYArimaHTanakaK, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke2003; 34:2349–2354.
32.
WuZYaoCZhaoDWuGWangWLiuJ, et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part I: morbidity and mortality monitoring. Circulation2001; 103:462–468.
33.
Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis2004; 172:95–105.
34.
BrittonAShipleyMMarmotMIHemingwayH. Does access to cardiac investigation and treatment contribute to social and ethnic differences in coronary heart disease? Whitehall II prospective cohort study. BMJ2004; 329:318–326.
35.
WoodDA. Preventing clinical heart failure: the rationale and scientific evidence. Heart2002; 88 (Suppl 2):ii15–22.
